Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

allogeneic anti-CD123 CAR-NK cells JD123

A preparation of off-the-shelf (OTS), allogeneic natural killer (NK) cells engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) human interleukin-3 receptor alpha chain (IL3RA; cluster of differentiation 123; CD123), with potential immunomodulating and antineoplastic activities. Upon administration, allogeneic anti-CD123 CAR-NK cells JD123 recognize, bind to and induce selective cytotoxicity in CD123-expressing tumor cells. CD123 is normally expressed on committed blood progenitor cells in the bone marrow; its overexpression is associated with both increased leukemic cell proliferation and aggressiveness.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:allogeneic CD123-targeted CAR NK cells JD123
Code name:JD 123
JD-123
JD123
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search